Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Badrising SK, van der Noort V, Hamberg P, Coenen JL, Aarts MJ, van Oort IM, van den Eertwegh AJ, Los M, van den Berg HP, Gelderblom H, Vrijaldenhoven S, Kerver ED, van Voorthuizen T, de Jong IJ, Haanen JB, Bergman AM; Dutch Uro-Oncology Study Group (DUOS). Badrising SK, et al. Among authors: van oort im, van voorthuizen t, van den eertwegh aj, van den berg hp, van der noort v. Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20. Oncology. 2016. PMID: 27544669
Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM. Hinnen KA, et al. Among authors: van oort im, van roermund jg, van vulpen m, van der poel h. J Clin Oncol. 2011 Dec 1;29(34):4510-5. doi: 10.1200/JCO.2011.35.0991. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025166
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Among authors: van oort im, van den eertwegh aj, van den berg hp, van tinteren h, van der noort v. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.
Self-reported acne is not associated with prostate cancer.
Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, van de Kerkhof PC, Schalken JA, Kiemeney LA. Cremers RG, et al. Among authors: van oort im, van de kerkhof pc. Urol Oncol. 2014 Oct;32(7):941-5. doi: 10.1016/j.urolonc.2014.02.019. Epub 2014 Jul 8. Urol Oncol. 2014. PMID: 25011577
Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.
Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Ploussard G, et al. Among authors: van oort im, van den bergh rc, van der poel hg. Urol Oncol. 2015 Feb;33(2):71.e1-9. doi: 10.1016/j.urolonc.2014.07.007. Epub 2014 Aug 15. Urol Oncol. 2015. PMID: 25131660
Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
Surcel CI, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Surcel CI, et al. Among authors: van oort im, van den bergh rc. Urol Oncol. 2015 Jun;33(6):265.e1-7. doi: 10.1016/j.urolonc.2014.08.007. Epub 2014 Sep 17. Urol Oncol. 2015. PMID: 25238700 Review.
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Among authors: van oort im, van den eertwegh aj, van den berg p. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736 Free article.
164 results